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Advanced heart failure is the most frequent diagnosis in
adult patients admitted to the hospital. The prevalence of
heart failure has increased as options for treatment have
improved. In addition to pharmacologic therapies, standard
implantable cardioverter-deﬁbrillators (ICDs) and cardiac
resynchronization therapy deﬁbrillators (CRT-D) have
decreased mortality and improved quality of life. Left
ventricular assist devices (LVAD) are also effective ther-
apeutic devices for patients with advanced heart failure,1 and
concurrent therapy with an LVAD and CRT-D is not
uncommon. Inappropriate ICD therapy due to electromag-
netic interference (EMI) has been reported with LVADs,2
and ICD–LVAD interactions sometimes require lead repo-
sitioning or even device removal.3 Fortunately, some current
ICDs have novel detection and pacing algorithms that can
prevent the need for invasive therapy to treat these inter-
actions. The present report adds signiﬁcantly to the literature
on LVADs and cardiac implantable electronic devices by
demonstrating how certain ICDs may be programmed to
preserve appropriate pacing for bradycardia without com-
promising the ability of the device to detect and treat
ventricular tachycardia and ventricular ﬁbrillation.Case presentation
A 73-year-old man with ischemic cardiomyopathy, long-
standing persistent atrial ﬁbrillation, third-degree atrioven-
tricular block, and advanced heart failure underwent LVAD
implantation (HeartMate II; Thoratec, Pleasanton, Califor-
nia) as destination therapy. The patient had undergone CRT-
D implantation (St. Jude Medical, St. Paul, Minnesota) a yearKEYWORDS Ventricular assist devices; Implantable cardioverter-
deﬁbrillator; Pacemaker; Cardiac resynchronization therapy;
Electromagnetic interference; Bradycardia; Ventricular tachycardia
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he had been active at home for more than 2 years. He then
presented for hospital admission with progressive low back
pain and lower-extremity weakness and was diagnosed with
lumbar vertebral compression. Telemetry monitoring dem-
onstrated multiple 2-second pauses despite having the CRT-
D programmed DDD with a heart rate of 90 beats per minute
(Figure 1A). Evaluation of the CRT-D device (St. Jude Unify
Quadra 3249-40) demonstrated atrial ﬁbrillation and normal
lead parameters during initial testing. A review of the device
electrograms during biventricular pacing and a ventricular
sensing amplitude test showed that ventricular pacing was
inhibited because of periodic right ventricular (RV) lead
sensing of low-amplitude electrograms (Figure 1B). The RV
lead impedance and capture threshold were normal. Decreas-
ing the RV pacing sensitivity (increasing the threshold value
to a higher number) was not effective in preventing these
sensed events because the sensitivity threshold would decay
signiﬁcantly during the time intervals between the previous
paced event and low-amplitude signal. What is the most
likely cause of these low-amplitude signals? How should the
device be reprogrammed to avoid inappropriate inhibition of
pacing while preserving appropriate sensing of ventricular
ﬁbrillation? Is RV lead repositioning necessary, or is there an
appropriate programming change that could ﬁx the problem?Commentary
Diagnosis
The differential diagnosis in this case includes appropriate
sensing or inappropriate sensing from one of the following:
myopotentials, ambient EMI, a lead fracture, a loose set
screw, mechanical interference from the LVAD, or EMI
from the LVAD. A lead fracture was unlikely with the
normal impedance, and isometric measures in the pocket did
not reproduce the interference. The discrete potentials were
also atypical for myopotentials. The 2-dimensional and
3-dimensional computed tomography images (Figure 2)
show very close proximity of the LVAD cannula to the
RV pacing/deﬁbrillating lead, making it most likely that thepen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Interactions between left ventricular assist devices
(LVADs) and implantable cardioverter-deﬁbrillators
(ICDs) are more likely when the sensing lead in a
transvenous system or the device in a subcutaneous
system is in close proximity to the LVAD cannula.
 The likelihood of this electromagnetic interference
(EMI) depends on the type of LVAD implanted and
can lead to both inappropriate sensing of
ventricular tachycardia and inhibition of
bradycardia pacing.
 Typical programming strategies to resolve
inappropriate ICD sensing from LVAD-associated
EMI, such as adjusting sensitivities, refractory
periods, decay delay parameters, or sensing ﬁlters
interaction, may not be adequate to prevent an
invasive device revision procedure.
 When these usual programming strategies are not
effective, a novel algorithm that allows setting
separate sensitivities for tachycardia detection and
bradycardia pacing can resolve these interactions
and prevent the need for additional invasive
procedures.
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mechanical interaction. Furthermore, evaluation of the
patient’s HeartMate II LVAD showed normal ﬂows and
power. Of note, HeartMate II and HeartWare VAD (HVAD;
Thoratec, Pleasanton, CA) are the most commonly used
LVADs in clinical practice. Although both generate electro-
magnetic ﬁelds, they operate at different pump speeds:
2400–3200 rpm for the HVAD and 8000–12,000 rpm for
the HeartMate II. Interestingly, there is not necessarily a
proportional relationship between LVAD pump speeds and
EMI, as our institutional experience and that of others has
been that the HeartMate II less frequently causes EMI
compared with the HVAD, even though it uses a higher
pump speed, as discussed below in the section “LVAD
interactions with other types of ICDs.”ICD–LVAD interactions
Previously identiﬁed interactions between ICD and LVADs
have included EMI from oversensing of extracardiac signals,
which can result in inappropriate therapies.4 Lead revisions
and generator replacements frequently have been required to
resolve this problem. As a result, it is recommended that
patients have their ICDs checked at the time of LVAD
surgery to evaluate EMI. An ICD–LVAD interaction, less
frequently seen now, would result in the inability to
communicate with older models of St. Jude ICDs.5,6 These
devices used an 8-kHz telemetry frequency, which is close to
that of the HeartMate II pulse width modulator. Metalshielding was used to bypass the pulse width modulator of
the LVAD and circumvent this interaction, but generator
replacement was often required. Of note, the pulse width
modulator of the HeartMate II LVAD is used to reduce the
12-volt battery voltage needed to power the motor. More
recent ICD models from St. Jude, as well as those made by
Biotronik, Medtronic, and Boston Scientiﬁc, use a greater
telemetry frequency, which makes this type of interaction
much less likely.
In our patient, with a newer St. Jude ICD model, telemetry
was intact but EMI from the LVAD appeared to be the most
likely cause. Initial programming attempts to ﬁx the problem
included lengthening the postventricular atrial refractory
period, increasing the postventricular atrial blanking period,
and reducing the sensitivity, but these interventions were not
effective. Because the sensed deﬂection appeared much later
than the prior ventricular event, the sensitivity would decay
much sooner and still sense the low-amplitude signal. The
other concern about reducing the RV sensitivity was
increasing the probability of undersensing of ventricular
tachycardia or ﬁbrillation and withholding appropriate ther-
apy for these arrhythmias. Adjusting the decay delay
parameter, which determines the amount of time after a
sensed or paced event that the sensing threshold remains at
the programmed value prior to decreasing, did not resolve
the problem because the oversensed electrograms occurred
well after the last ventricular event. The high attenuation
ﬁlter was also considered, but this would have required
deﬁbrillation threshold testing and potentially inhibited
appropriate sensing of ventricular tachyarrhythmias.Resolution of EMI interaction in the present case
Considering that standard programming changes did not
resolve the problem, it is fortunate that this patient’s St. Jude
ICD had the SenseAbility algorithm, as it was this algorithm
that ultimately resolved the problem. Because many electro-
physiologists may not be familiar with this algorithm, we
highlight here why it was effective when other measures
failed. There are several features of this algorithm that help
prevent oversensing of low-amplitude signals. Speciﬁcally,
this algorithm permits decoupling of ventricular pacing
sensitivity and ventricular deﬁbrillator sensitivity. This
approach facilitates adjustment of the sensitivity of RV
pacing to minimize oversensing without compromising the
sensitivity of tachyarrhythmia detection. The device had
been programmed at the time of implantation to a nominal
ventricular pacing and deﬁbrillation sensitivity of 0.5 mV.
To address the inappropriate pacing inhibition during the
present admission, the sensitivity for RV pacing was
reprogrammed to 2 mV, but the deﬁbrillation sensitivity
was maintained at 0.5 mV (Figure 3A), thus allowing for
both maintenance of pacing for bradycardia and appropriate
detection of ventricular tachyarrhythmias. In other words, the
algorithm allows different sensitivities to be programmed for
bradycardia pacing and tachyarrhythmia detection. The
repeat device interrogation with these new settings revealed
Figure 1 Telemetry and initial interrogation. A: The telemetry strip shows frequent pauses and pacing inhibition. B: Device electrograms before and during a
ventricular sensing amplitude test include low-amplitude signals on the ventricular channel that inhibit pacing and are inappropriately sensed as intrinsic beats
during the sensing test. The magniﬁed box shows a far-ﬁeld ventricular electrogram of amplitude 0.7 mV that is inappropriately sensed after a ventricular paced
beat. The atrial electrograms (not included) showed atrial ﬁbrillation.
475Murphy et al Pacing Inhibition With LVADssimilar low-amplitude electrograms on the RV lead; how-
ever, pacing immediately followed sensing of these far-ﬁeld
events without inhibition by these signals (Figure 3B). This
example of appropriate ventricular pacing following detec-
tion of far-ﬁeld electrograms contrasts with more common
algorithms to prevent oversensing that involve blanking of
far-ﬁeld electrograms or marking them as refractory. In
summary, this algorithm likely prevented an ICD revision
procedure in this patient, as none of the other programming
solutions were able to resolve the problem.LVAD interactions with other types of ICDs
With respect to available options with other device manu-
facturers, Medtronic transvenous ICDs have an RV lead
noise discrimination feature, which compares the far-ﬁeldelectrogram signals to the near-ﬁeld electrograms in order
to differentiate RV lead noise from true ventricular arrhyth-
mias. If lead noise is identiﬁed when these signals are
compared, ventricular arrhythmia detection and therapy
are withheld. Other features used for discrimination in
Medtronic devices include PR logic, wavelet, T-wave
discrimination, onset, and stability, which may have a role
in discriminating low-amplitude EMI. In patients with
Boston Scientiﬁc subcutaneous ICDs (S-ICDs), there have
been reported interactions with the HVAD,7 as the frequency
of the signals generated by the electromagnetic ﬁeld of
the HVAD is within the range of the signals detectable by
the S-ICD. The relationship between pump speeds and EMI
is controversial, as a recent case report suggested that
the HeartMate II is actually safe in patients with S-ICDs
despite high pump speeds, with no interference detected in
Figure 2 Three-dimensional (3D) imaging of the implantable cardioverter-deﬁbrillator leads and left ventricular assist device. The 3D reconstruction of the
chest computed tomography (CT) (A) and the corresponding 2-dimensional CT image in the axial plane (B) demonstrate the close proximity of the right
ventricular lead tip to left ventricular apical cannula.
Heart Rhythm Case Reports, Vol 2, No 6, November 2016476both the vectors involving the pulse generator and the
alternative vector using the distal lead electrode and
proximal ring.8 However, in another case involving an
HVAD, this alternative S-ICD was reported to be associated
with less EMI compared with the vectors using the gene-
rator (in closer proximity to the LVAD cannula).7 As a
result, in some patients with HVADs, inappropriate therapies
may be avoided based on using this alternative S-ICD
vector.Figure 3 Resolution with advanced device programming. A: The algorithm de
ventricular paced events occur shortly after inappropriately sensed events, whichConclusion
In the care of end-stage patients with concurrent LVADs
and ICDs, a heightened degree of awareness of potential
complications and interactions is needed. In this regard, the
present case highlights the complexity of LVAD–ICD
interactions and how resolution of a particular LVAD–ICD
interaction was achieved using a novel programming
algorithm, which helped avoid an invasive LVAD or
ICD revision procedure. Speciﬁcally, this novel algorithmcouples the right ventricular pacing and deﬁbrillation sensitivities. B: The
are ignored only for the purposes of pacing.
477Murphy et al Pacing Inhibition With LVADsallowed different sensitivities for bradycardia pacing and
ventricular tachyarrhythmia detection, which avoided inhib-
ition of pacing from inappropriately sensed events on the
ventricular channel. Application of the SenseAbility algo-
rithm to patients with ICDs, LVADs, and EMI has not
previously been reported, and familiarity with this algorithm
could help other arrhythmia specialists treat their patients
more effectively in the future. Minimizing pacing inhibition
in these patients, particularly those who are pacemaker
dependent, is of great clinical importance. As cardiac devices
continue to evolve, it is critical for electrophysiology
providers to understand interactions between cardiac
implantable electronic devices and advanced surgical devi-
ces for end-stage heart failure, as well as how these problems
may be most appropriately addressed.
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